



IBA and Nelco enter co-marketing agreement to offer compact, proton therapy, modular shielding solutions in North America

Louvain-la-Neuve, Belgium, January 24 2017 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, is pleased to announce a co-marketing agreement in North America with Nelco Worldwide, the global leader in radiation shielding products and solutions to offer custom, modular radiation shielding solutions for Proteus®ONE*.

The Proteus®ONE solution has been developed by IBA to allow patients worldwide access to proton therapy. The compact, single-treatment-room proton therapy solution is smaller than existing standard systems, making it more affordable and therefore more accessible to clinical institutions. Proteus®ONE incorporates the latest in proton therapy technology, including Pencil Beam Scanning (PBS) and Cone-Beam CT (CBCT).

The Agilis1TM system is a custom, pre-engineered, modular solution that is exclusively developed by NELCO, to enable IBA to reduce time and costs associated with the complex shielding requirements of the Proteus®ONE equipment. "Our primary motivation for creating this first-of-its kind solution is to allow cancer centers to start treating patients sooner," said **Rick LeBlanc, President and CEO of NELCO Worldwide**.

Jason Koshnitsky, Product Director of IBA North America, commented "We chose NELCO as our preferred vendor because of their excellent reputation and track record in developing and deploying shielding solutions for the radiotherapy market. Their custom Agilis offering was specifically developed for our Proteus®ONE with the intention of reducing time and cost associated with building a proton therapy center."

Mr. LeBlanc, added "We are very enthused to be working with such an innovative, dynamic, and world-class company. This is a perfect partnership between two powerhouse entities dedicated to the advancement of proton therapy for patients and healthcare organizations across the North America."

*Proteus®ONE is the brand names of the Proteus®235.



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.

About NELCO

As the global leader in radiation shielding solutions, NELCO Worldwide protects the health and safety of employees, customers and the public across 6 continents and 35 countries. For more than 85 years, NELCO has led the industry with innovative technologies, products, and services to support the many needs of medical equipment manufacturers, clinical and design teams, and c-level executives. NELCO has completed projects in the top 10 U.S. cancer centers and 48 of the top 50, has provided shielding solutions for more than 3,500 vaults, and installed over 4,400 shielded door systems. NELCO is headquartered in Boston, Massachusetts. To learn more about NELCO, visit www.nelcoworldwide.com.



Contact for further information:

IBA:

Jana Kulhankova

Marketing Associate Proton Therapy
+32 10 203652
jana.kulhankova@iba-group.com

Thomas Ralet

Vice-President Corporate Communication
+32 10 47 58 90
communication@iba-group.com